Brain Corp: Transforming everyday machines into autonomous solutions

Beam Therapeutics uses CRISPR base editing to develop genetic medicines

Genprex: developing the immunogene therapy for cancer

A mobile application to support education of dyslexic children

Dyslexia is defined as a neurological difference in acquiring reading, spelling and writing skills by the European Dyslexia Association, and is seen in individuals with both average and above-average intellect. Thought to have affected geniuses such as Einstein, Mozart and Leonardo da Vinci, dyslexia is usually discovered in the first years of primary school as it affects reading skills. However, Sabancı University Faculty of Engineering and Natural Sciences Computer Science and Engineering PhD Candidate Günet Eroğlu developed 'Auto Train Brain', a mobile application for dyslexic children having academic and learning difficulties.

3 days ago

CloudCuddle provides mobile and safe sleeping environment for disabled children

CloudCuddle develops a safe sleeping environment for physically and/or mentally impaired children. The company is spinoff of Delft University of Technology (TUDelft). The CloudCuddle team consists of Francesca Lucas and Lotte Leufkens. They started development during their minor Biomechanical Engineering and decided to continue their efforts after positive feedback from families that could use their product. After winning multiple competitions with their idea, developing full-size prototypes and a business plan around the product, they are now working hard to get the product to market.

7 days ago

Inflazome provides targeted therapies for inflammatory diseases

Inflazome is a biotech company that develops new drugs to block harmful inflammation. The company is creating potent and selective small-molecule inhibitors of the NLRP3 inflammasome, to stop the cycle of chronic inflammation that drives Alzheimer’s (lat. morbus Alzheimerianus) and Parkinson’s diseases (lat. Parkinson scriptor morbus) as well as inflammatory bowel disease, gout, osteoarthritis, liver, kidney and cardiovascular diseases. Inflazome has already secured further investment of $63 million. Launched in 2016, Inflazome was founded on research from The University of Queensland and Trinity College Dublin in Ireland. The Series B financing will be used to advance the company's small-molecule inhibitors of the NLRP3 inflammasome in to multiple clinical trials in 2019.

8 days ago

Corsair FEAM: Better Protection from Impact Injury

Umoove allows mobile a face and eye tracking

Beats Medical - a technology solution for people with Parkinson's disease

Global Kinetics provides a continuous assessment of movement disorder symptoms

Global Kinetics Pty Ltd. is committed to improving the lives of those with Parkinson's disease with advanced medical technologies. The company was formed in order to commercialise its lead product, the Personal KinetiGraph™ (PKG™), also known as the Parkinson's KinetiGraph™ outside the USA. Developed in conjunction with the world-renowned Florey Institute of Neuroscience & Mental Health in Melbourne, Australia, the PKG enables the precise monitoring, quantification, and reporting of movement symptoms in Parkinson's. To date, Global Kinetics has supported clinical decisions for doctors who treat patients with Parkinson's disease across 17 countries with more than 3,000,000 hours of clinical data from our FDA-cleared, CE-marked PKG wearable device. Global Kinetics, a privately held company, is headquartered in Melbourne, Australia with offices in London, UK, Minneapolis, MN, and Portsmouth, NH, USA.

20 days ago

Breakthrough treatments for CNS Diseases

PolyCore Therapeutics LLC is a drug development company spinoff from Drexel University focused on the development of products for CNS disorders. The initial product in development, PCT-3010, is a biased signaling D3 agonist, a breakthrough once-a-day oral therapy for Parkinson’s disease (lat. Parkinson scriptor morbus) that improves motor symptoms without the development of drug tolerance or dyskinesia. The product will be utilized as monotherapy or as an adjunct to L-dopa to prolong the efficacy time of L-dopa and reduce L-dopa induced dyskinesia. This is a six billion per year market opportunity in the US.

22 days ago

Heliex Power: harnessing the power of steam

Heliex Power Ltd. is a spinoff of the City, University of London (CITY UL) that develops steam screw expanders. It offers expander systems including self-contained, skid-mounted generator sets. The company's products are used in the electricity generation, petrochemical, glass and refractories, pharmaceuticals, food, brewing and distilling, paper production, biomass, and other industries. With systems across Europe in industries from glass and farming, to steel and chemicals plus a portfolio of four truly unique products, Heliex continues on its mission to cut energy costs in the industry and boost sustainability in a multitude of sectors across the globe.  The company is based in East Kilbride, United Kingdom.

22 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.



100% Free of Cost For Scientists:

  • One hour of USA/EU attorney consulting
  • 24/7 support of 24 in-house professionals
  • 10 GB space for every scientist (own German Servers)
  • Syndicates with the leading professionals
  • 2,000 000 views of top spinoff are guaranteed
  • The largest DB of professional Investors - over 30.000

100% Free of Cost For Investors:

  • Investment information on 8,000+ spinoffs per year
  • All documents in one place (after NDA)
  • Testimonials from Key Opinion Leaders
  • AI-SDB hides irrelevant spinoffs - saved time up to 90% 
  • One-Click-Reports (OCRs) in own tailored design (PDF)

100% Free of Cost For Universities:

  • Professional Science Spinoff University Report (PDF)
  • No Links to - Ready to Print and Share
  • Professional dossiers on over 27Tsd VC/PE/FO/ML
  • Professional dossiers on over 3Tsd MNC